These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23055780)

  • 1. A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials.
    Tack J; Wyndaele JJ; Ligozio G; Egermark M
    Drug Healthc Patient Saf; 2012; 4():127-39. PubMed ID: 23055780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
    Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
    BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for preventing postpartum constipation.
    Turawa EB; Musekiwa A; Rohwer AC
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011625. PubMed ID: 26387487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
    Foote J; Glavind K; Kralidis G; Wyndaele JJ
    Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F; Stewart L; Dwyer P
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
    Zinner N; Kobashi KC; Ebinger U; Viegas A; Egermark M; Quebe-Fehling E; Koochaki P
    Int J Clin Pract; 2008 Nov; 62(11):1664-74. PubMed ID: 18811599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.
    Manjunatha R; Pundarikaksha HP; Hanumantharaju BK; Anusha SJ
    J Clin Diagn Res; 2015 Mar; 9(3):FC05-9. PubMed ID: 25954630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
    Wagg A; Compion G; Fahey A; Siddiqui E
    BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
    Hill S; Elhilali M; Millard RJ; Dwyer PL; Lheritier K; Kawakami FT; Steel M
    Curr Med Res Opin; 2007 Nov; 23(11):2697-704. PubMed ID: 17892634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osmotic and stimulant laxatives for the management of childhood constipation.
    Gordon M; Naidoo K; Akobeng AK; Thomas AG
    Cochrane Database Syst Rev; 2012 Jul; (7):CD009118. PubMed ID: 22786523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.
    Meek PD; Evang SD; Tadrous M; Roux-Lirange D; Triller DM; Gumustop B
    Dig Dis Sci; 2011 Jan; 56(1):7-18. PubMed ID: 20596778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W; Corcos J; Foote J; Kralidis G
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
    Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
    Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.